Research location

Andalusia

Alabama, United States

Published trials29

Site observations30

Linked trials published29

Page1 / 1

Research activity in Andalusia

Alabama, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 29 trials and 30 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Andalusia

29 linked trials · page 1 of 1

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsNCT06857955 · 2025-03-26 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPDNCT04882124 · 2021-09-24 · 1 site observation

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)NCT04636814 · 2021-07-12 · 1 site observation

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDNCT04542057 · 2020-09-22 · 1 site observation

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to InhaleNCT04223843 · 2020-01-08 · 1 site observation

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD PatientsNCT04072887 · 2019-09-12 · 1 site observation

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 InflammationNCT03930732 · 2019-04-15 · 1 site observation

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT03474081 · 2018-03-29 · 1 site observation

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device RobustnessNCT03137992 · 2017-11-21 · 1 site observation

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled AsthmaNCT03226392 · 2017-10-31 · 1 site observation

Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)NCT03256695 · 2017-09-28 · 1 site observation

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF PatientsNCT03066804 · 2017-08-22 · 1 site observation

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT03118765 · 2017-03-24 · 1 site observation

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes MellitusNCT03086330 · 2017-03-15 · 1 site observation

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection FractionNCT02884206 · 2016-11-23 · 1 site observation

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)NCT02497001 · 2015-08-10 · 1 site observation

Efficacy and Safety Study of QVA149 in COPD PatientsNCT02487446 · 2015-07-28 · 1 site observation

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)NCT02465567 · 2015-06-30 · 1 site observation

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPDNCT02343458 · 2015-03-30 · 1 site observation

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)NCT02347774 · 2015-02-01 · 1 site observation

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.NCT02296138 · 2015-01-13 · 1 site observation

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABANCT02258542 · 2014-11-19 · 1 site observation

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPDNCT02276222 · 2014-10-01 · 1 site observation

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary DiseaseNCT02157935 · 2014-06-27 · 2 site observations

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation HistoryNCT02138916 · 2014-06-13 · 1 site observation

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)NCT01970878 · 2013-11-01 · 1 site observation

Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 AgonistNCT01914757 · 2013-08-01 · 1 site observation

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)NCT01854645 · 2013-05-01 · 1 site observation

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseNCT01313676 · 2011-01-25 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.